

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (currently amended) A compound consisting of a total of 8-50 nucleotides and/or nucleotide analogues, wherein said compound comprises a subsequence of at least 8 nucleotides or nucleotide analogues, said subsequence being located within a sequence selected from the group consisting of SEQ ID NOS: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143 and 144.
2. (original) The compound according to claim 1, said subsequence being located within a sequence selected from the group consisting of SEQ ID NOS: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132 and 133.
3. (currently amended) The compound according to claim 1 or 2 consisting of from 8-40 nucleotides.
4. (original) The compound according to claim 3 consisting of from 8-20 nucleotides.

5. (currently amended) The compound according to claim 4 consisting of from 12-20 nucleotides.
6. (original) The compound according to claim 5 consisting of 12, 13, 14, 15, 16, 17, 18, 19 or 20 nucleotides.
7. (original) The compound according to claim 6 consisting of 14, 15, 16, 17 or 18 nucleotides.
8. (original) The compound according to claim 5 consisting of from 15-17 nucleotides.
9. (original) The compound according to claim 8 consisting of 15, 16 or 17 nucleotides.
10. (original) The compound according to claim 8 consisting of 15 nucleotides.
11. (original) The compound according to claim 9 consisting of 16 nucleotides.
12. (original) The compound according to claim 9 consisting of 17 nucleotides.
13. (currently amended) The compound according to ~~any one of the preceding claims~~ claim 1, comprising a subsequence of at least 10 nucleotides or nucleotide analogues.
14. (currently amended) The compound according to ~~any one of the preceding claims~~ claim 1, comprising a subsequence of at least 12 nucleotides or nucleotide analogues.
15. (currently amended) The compound according to ~~any one of the preceding claims~~ claim 1, comprising a subsequence of at least 14 nucleotides or nucleotide analogues.

16. (currently amended) The compound according to ~~any one of claims 1 to 13~~ claim 1, comprising a subsequence of 10, 11, 12, 13 14 15 or 16 nucleotides or nucleotide analogues.

17. (currently amended) The compound according to ~~any of claims 1-16~~ claim 1, wherein said nucleotides comprise a linkage group selected from the group consisting of -O-P(O)₂-O-, -O-P(O,S)-O-, -O-P(S)₂-O-, -S-P(O)₂-O-, -S-P(O,S)-O-, -S-P(S)₂-O-, -O-P(O)₂-S-, -O-P(O,S)-S-, -S-P(O)₂-S-, -O-PO(R^H)-O-, O-PO(OCH₃)-O-, -O-PO(NR^H)-O-, -O-PO(OCH₂CH₂S-R)-O-, -O-PO(BH₃)-O-, -O-PO(NHR^H)-O-, -O-P(O)₂-NR^H-, -NR^H-P(O)₂-O-, -NR^H-CO-O-, -NR^H-CO-NR^H-, -O-CO-O-, -O-CO-NR^H-, -NR^H-CO-CH₂-, -O-CH₂-CO-NR^H-, -O-CH₂-CH₂-NR^H-, -CO-NR^H-CH₂-, -CH₂-NR^H-CO-, -O-CH₂-CH₂-S-, -S-CH₂-CH₂-O-, -S-CH₂-CH₂-S-, -CH₂-SO₂-CH₂-, -CH₂-CO-NR^H-, -O-CH₂-CH₂-NR^H-CO-, -CH₂-NCH₃-O-CH₂-, where R^H is selected from hydrogen and C₁₋₄-alkyl.

18. (currently amended) The compound according to ~~any of claims 1-17~~ claim 1, wherein said nucleotides comprise a linkage group selected from the group consisting of a phosphate group, a phosphorothioate group and a boranophosphate group.

19. (original) The compound according to claim 18, wherein said linkage is a phosphate group.

20. (original) The compound according to claim 17, wherein said linkage is phosphorothioate group.

21. (original) The compound according to claim 20, wherein all nucleotides comprise a phosphorothioate group.

22. (currently amended) The compound according to ~~any of the preceding claims~~ claim 1, wherein at least one nucleotide is replaced by a corresponding nucleotide analogue.

23. (original) The compound according to claim 22 comprising of from 1-50 nucleotide analogues.

24. (original) The compound according to claim 23 comprising of from 2-45 nucleotide analogues.

25. (original) The compound according to claim 24 comprising of from 3-40 nucleotide analogues.

26. (original) The compound according to claim 25 comprising of from 4-35 nucleotide analogues.

27. (original) The compound according to claim 26 comprising of from 5-30 nucleotide analogues.

28. (original) The compound according to claim 27 comprising of from 6-25 nucleotide analogues.

29. (original) The compound according to claim 28 comprising of from 6-20 nucleotide analogues.

30. (original) The compound according to claim 29 comprising of from 6-12 nucleotide analogues.

31. (original) The compound according to claim 30 comprising of from 8-12 nucleotide analogues.

32. (original) The compound according to claim 30 comprising 6, 7, 8, 9, 10, 11 or 12 nucleotide analogues.

33. (original) The compound according to claim 31 comprising of from 6-10 nucleotide analogues.

34. (original) The compound according to claim 33 comprising 6, 7, 8, 9 or 10 nucleotide analogues.


35. (original) The compound according to claim 34 comprising 7, 8 or 9 nucleotide analogues.

36. (original) The compound according to claim 35 comprising 8 nucleotide analogues.

37. (original) The compound according to any of claims 22-36, wherein all nucleotides are replaced by the corresponding nucleotide analogues.

38. (original) The compound according to any of claims 22-36 comprising a nucleoside located at the 3' end.

[[40]] 39. (currently amended) The compound according to ~~any of claims 22-39~~ claim 22, wherein at least one of said nucleotide analogues is a locked nucleic acid (LNA) of the formula



wherein Z and Z* are independently absent, selected among an internucleoside linkage, a terminal group or a protecting group;

X and Y are independently selected from the group consisting of O, S, NR, CH₂, CH, (if part of a double bond), CH₂-O, CH₂-S, CH₂-NR, CH₂-CH₂, CH₂-CH (if part of a double bond) and CH=CH, where R is hydrogen or C₁₋₄-alkyl.

[[41]] 40. (currently amended) The compound according to claim [[40]] 39, wherein X is O and Y is selected from the group consisting of O, S and NR, where R is hydrogen or C₁₋₄-alkyl.

[[42]] 41. (currently amended) The compound according to claim [[41]] 40, wherein X is O and Y is selected from the group consisting of O, S and NH.

[[43]] 42. (currently amended) The compound according to claim [[42]] 41, wherein X is O and Y is O.

[[44]] 43. (currently amended) The compound according to ~~any of claims 40-46~~ claim 39, wherein said LNA is in the β -D or α -L also form, preferably the β -D form.

[[45]] 44. (currently amended) The compound according to ~~any of claims 40-44~~ claim 39, wherein said nucleotides analogues comprise a linkage group selected from the group consisting of -O-P(O)₂-O-, -O-P(O,S)-O-, -O-P(S)₂-O-, -S-P(O)₂-O-, -S-P(O,S)-O-, -S-P(S)₂-O-, -O-P(O)₂-S-, -O-P(O,S)-S-, -S-P(O)₂-S-, -O-PO(R^H)-O-, O-PO(OCH₃)-O-, -O-PO(NR^H)-O-, -O-PO(OCH₂CH₂S-R)-O-, -O-PO(BH₃)-O-, -O-PO(NHR^H)-O-, -O-P(O)₂-NR^H-, -NR^H-P(O)₂-O-, -NR^H-CO-O-, -NR^H-CO-NR^H-, -O-CO-O-, -O-CO-NR^H-, -NR^H-CO-CH₂-, -O-CH₂-CO-NR^H-, -O-CH₂-CH₂-NR^H-, -CO-NR^H-CH₂-, -CH₂-NR^H-CO-, -O-CH₂-CH₂-S-, -S-CH₂-CH₂-O-, -S-CH₂-CH₂-S-, -CH₂-SO₂-CH₂-, -CH₂-CO-NR^H-, -O-CH₂-CH₂-NR^H-CO -, -CH₂-NCH₃-O-CH₂-, where R^H is selected form hydrogen and C₁₋₄-alkyl.

[[46]] 45. (currently amended) The compound according to claim [[45]] 44, wherein said nucleotides and/or nucleotide analogues are linked to each other by means of a phosphate group.

[[47]] 46. (currently amended) The compound according to claim [[45]] 44, wherein said nucleotides and/or nucleotide analogues are linked to each other by means of a phosphorothioate group.

[[48]] 47. (currently amended) The compound according to claim [[47]] 46, wherein said nucleotides and/or nucleotide analogues are linked to each other by means of a phosphorothioate group, X is O and Y is O, and said LNA is in the β -D form.

[[49]] 48. (currently amended) The compound according to any of claims [[45-48]] 44-47, wherein said subsequence comprises a stretch of 2-6 LNAs as defined in any of claims [[40-44]] 39-43 followed by a stretch of 4-12 nucleotides, which is followed by a stretch of 2-6 LNAs as defined in any of claims [[40-44]] 39-43.

[[50]] 49. (currently amended) The compound according to claim [[49]] 48, wherein said subsequence comprises a stretch of 4 LNAs as defined in any of claims [[40-44]] 39-43 followed by a stretch of 8 nucleotides, which is followed by a stretch of 4 LNAs as defined in any of claims [[40-44]] 39-43.

[[51]] 50. (currently amended) The compound according to claim [[48]] 47, wherein said subsequence comprises a stretch of 2-6 LNAs as defined in any of claims [[40-44]] 39-43 followed by a stretch of 4-12 nucleotides, which is followed by a stretch of 2-5 LNAs as defined in any of claims [[40-44]] 39-43, which is followed by a single nucleotide.

[[52]] 51. (currently amended) The compound according to claim [[51]] 50, wherein said subsequence comprises a stretch of 4 LNAs as defined in any of claims [[40-44]] 39-43 followed by a stretch of 8 nucleotides, which is followed by a stretch of 3 LNAs as defined in any of claims [[40-44]] 39-43, which is followed by a single nucleotide.

[[53]] 52. (currently amended) The compound according to claim ~~51 or 52~~, wherein said single nucleoside is located at the 3' end.

[[54]] 53. (currently amended) The compound according to ~~any of claims 49-53~~ claim 48, wherein said nucleosides and/or LNAs are linked to each other by means of a linkage group selected from the group consisting of a phosphate group, a phosphorothioate group and a boranophosphate group.

[[55]] 54. (currently amended) The compound according to claim [[54]] 53, wherein said nucleosides and/or said LNAs are linked together by means of phosphate groups.

[[56]] 55. (currently amended) The compound according to claim [[54]] 53, wherein said nucleosides and/or said LNAs are linked together by means of phosphorothioate groups.

[[57]] 56. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~2a~~ 147.

[[58]] 57. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~3a~~ 151.

[[59]] 58. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~4a~~ 155.

[[60]] 59. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~5a~~159.

[[61]] 60. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~6a~~163.

[[62]] 61. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~7a~~167.

[[63]] 62. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~8a~~171.

[[64]] 63. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~9a~~175.

[[65]] 64. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~10a~~179.

[[66]] 65. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~11a~~183.

[[67]] 66. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~12a~~187.

[[68]] 67. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~13a~~191.

[[69]] 68. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~14a~~-195.

[[70]] 69. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~15a~~-199.

[[57]] 70. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~117a~~-608.

[[57]] 71. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~118a~~-612.

[[58]] 72. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~119a~~-616.

[[59]] 73. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~120a~~-620.

[[60]] 74. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~121a~~-624.

[[61]] 75. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~122a~~-628.

[[62]] 76. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~123a~~-632.

[[63]] 77. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~124a~~-636.

[[64]] 78. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~125a~~-640.

[[65]] 79. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~126a~~-644.

[[66]] 80. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~127a~~-648.

[[67]] 81. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~128a~~-652.

[[68]] 82. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~129a~~-656.

[[69]] 83. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~130a~~-660.

[[70]] 84. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~131a~~-664.

[[71]] 85. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~132a~~-668.

[[72]] 86. (currently amended) The compound according to claim [[56]] 55, wherein the subsequence is SEQ ID NO: ~~133a~~672.

[[73]] 87. (currently amended) The compound according to any of claims [[57-72]] 56-86, wherein the 3' end LNA is replaced by the corresponding natural nucleoside.

[[74]] 88. (currently amended) A compound consisting of SEQ ID NO: ~~2a~~147.

[[75]] 89. (currently amended) A compound consisting of SEQ ID NO: ~~3a~~151.

[[76]] 90. (currently amended) A compound consisting of SEQ ID NO: ~~4a~~155.

[[77]] 91. (currently amended) A compound consisting of SEQ ID NO: ~~5a~~159.

[[78]] 92. (currently amended) A compound consisting of SEQ ID NO: ~~6a~~163.

[[79]] 93. (currently amended) A compound consisting of SEQ ID NO: ~~7a~~167.

[[80]] 94. (currently amended) A compound consisting of SEQ ID NO: ~~8a~~171.

[[81]] 95. (currently amended) A compound consisting of SEQ ID NO: ~~9a~~175.

[[82]] 96. (currently amended) A compound consisting of SEQ ID NO: ~~10a~~179.

[[83]] 97. (currently amended) A compound consisting of SEQ ID NO: ~~11a~~183.

[[84]] 98. (currently amended) A compound consisting of SEQ ID NO: ~~12a~~187.

[[85]] 99. (currently amended) A compound consisting of SEQ ID NO: ~~13a~~191.

[[86]] 100. (currently amended) A compound consisting of SEQ ID NO: ~~14a~~195.

[[87]] 101. (currently amended) A compound consisting of SEQ ID NO: ~~15a~~199.

[[88]] 102. (currently amended) A compound consisting of SEQ ID NO: ~~117a~~608.

[[89]] 103. (currently amended) A compound consisting of SEQ ID NO: ~~118a~~612.

[[90]] 104. (currently amended) A compound consisting of SEQ ID NO: ~~119a~~616.

[[91]] 105. (currently amended) A compound consisting of SEQ ID NO: ~~120a~~620.

[[92]] 106. (currently amended) A compound consisting of SEQ ID NO: ~~121a~~624.

[[93]] 107. (currently amended) A compound consisting of SEQ ID NO: ~~122a~~628.

[[94]] 108. (currently amended) A compound consisting of SEQ ID NO: ~~123a~~632.

[[95]] 109. (currently amended) A compound consisting of SEQ ID NO: ~~124a~~636.

[[96]] 110. (currently amended) A compound consisting of SEQ ID NO: ~~125a~~640.

[[97]] 111. (currently amended) A compound consisting of SEQ ID NO: ~~126a~~644.

[[98]] 112. (currently amended) A compound consisting of SEQ ID NO: ~~127a~~648.

[[99]] 113. (currently amended) A compound consisting of SEQ ID NO: ~~128a~~652.

[[100]] 114. (currently amended) A compound consisting of SEQ ID NO: ~~129a~~ 656.

[[101]] 115. (currently amended) A compound consisting of SEQ ID NO: ~~130a~~ 660.

[[102]] 116. (currently amended) A compound consisting of SEQ ID NO: ~~131a~~ 664.

[[103]] 117. (currently amended) A compound consisting of SEQ ID NO: ~~132a~~ 668.

[[104]] 118. (currently amended) A compound consisting of SEQ ID NO: ~~133a~~ 672.

[[105]] 119. (currently amended) The compound according to any of claims [[74-104]] 88-118, wherein the 3' end LNA is replaced by the corresponding nucleotide.

[[106]] 120. (currently amended) A conjugate comprising the compound according to ~~any of claims 1-73~~ claim 1 and at least one non-nucleotide or non-polynucleotide moiety covalently attached to said compound.

[[107]] 121. (currently amended) A pharmaceutical composition comprising a compound as defined in ~~any of claims 1-105~~ claim 1 or a conjugate as defined in claim [[106]] 120, and a pharmaceutically acceptable diluent, carrier or adjuvant.

[[108]] 122. (currently amended) The pharmaceutical composition according to claim [[107]] 121 further comprising at least one chemotherapeutic agent.

[[109]] 123. (currently amended) The pharmaceutical composition according to claim [[108]] 122, wherein said chemotherapeutic compound is selected from the group consisting of adrenocorticosteroids, such as prednisone, dexamethasone or decadron; altretamine (hexalen, hexamethylmelamine (HMM)); amifostine (ethyol); aminoglutethimide (cytadren); amsacrine (M-AMSA); anastrozole (arimidex); androgens, such as testosterone; asparaginase (elspar);

bacillus calmette-gurin; bicalutamide (casodex); bleomycin (blenoxane); busulfan (myleran); carboplatin (paraplatin); carmustine (BCNU, BiCNU); chlorambucil (leukeran); chlorodeoxyadenosine (2-CDA, cladribine, leustatin); cisplatin (platinol); cytosine arabinoside (cytarabine); dacarbazine (DTIC); dactinomycin (actinomycin-D, cosmegen); daunorubicin (cerubidine); docetaxel (taxotere); doxorubicin (adriomycin); epirubicin; estramustine (emcyt); estrogens, such as diethylstilbestrol (DES); etoposide (VP-16, VePesid, etopophos); fludarabine (fludara); flutamide (eulexin); 5-FUDR (floxuridine); 5-fluorouracil (5-FU); gemcitabine (gemzar); goserelin (zodalex); herceptin (trastuzumab); hydroxyurea (hydrea); idarubicin (idamycin); ifosfamide; IL-2 (proleukin, aldesleukin); interferon alpha (intron A, roferon A); irinotecan (camptosar); leuprolide (lupron); levamisole (ergamisole); lomustine (CCNU); mechlorathamine (mustargen, nitrogen mustard); melphalan (alkeran); mercaptopurine (purinethol, 6-MP); methotrexate (mexate); mitomycin-C (mutamucin); mitoxantrone (novantrone); octreotide (sandostatin); pentostatin (2-deoxycoformycin, nipent); plicamycin (mithramycin, mithracin); prorocarbazine (matulane); streptozocin; tamoxifen (nolvadex); taxol (paclitaxel); teniposide (vumon, VM-26); thiotepa; topotecan (hycamtin); tretinoin (vesanoid, all-trans retinoic acid); vinblastine (valban); vincristine (oncovin) and vinorelbine (navelbine).

[[110]] 124. (currently amended) A compound as defined in ~~any of claims 1-105~~ claim 1 or a conjugate as defined in claim [[106]] 120 for use as a medicament.

[[111]] 125. (currently amended) Use of a compound as defined in ~~any of claims 1-105~~ claim 1 or as conjugate as defined in claim [[106]] 120 for the manufacture of a medicament for the treatment of cancer.

[[112]] 126. (currently amended) Use according to claim [[111]] 125, wherein said cancer is in the form of a solid tumor.

[[113]] 127. (currently amended) Use according to claim [[111 or 112]] 125 or 126, wherein said cancer is a carcinoma.

[[114]] 128. (currently amended) Use according to claim [[113]] 127, wherein said carcinoma is selected from the group consisting of malignant melanoma, basal cell carcinoma, ovarian carcinoma, breast carcinoma, non-small cell lung cancer, renal cell carcinoma, bladder carcinoma, recurrent superficial bladder cancer, stomach carcinoma, prostatic carcinoma, pancreatic carcinoma, lung carcinoma, cervical carcinoma, cervical dysplasia, laryngeal papillomatosis, colon carcinoma, colorectal carcinoma and carcinoid tumors.

[[115]] 129. (currently amended) Use according to claim [[114]] 128, wherein said carcinoma is selected from the group consisting of malignant melanoma, non-small cell lung cancer, breast carcinoma, colon carcinoma and renal cell carcinoma.

[[116]] 130. (currently amended) Use according to [[115]] 129, wherein said malignant melanoma is selected from the group consisting of superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral melanoma, amelanotic melanoma and desmoplastic melanoma.

[[117]] 131. (currently amended) Use according to claim [[111 or 112]] 125 or 126, wherein said cancer is a sarcoma.

[[118]] 132. (currently amended) Use according to claim [[117]] 131, wherein said sarcoma is selected from the group consisting of osteosarcoma, Ewing's sarcoma, chondrosarcoma, malignant fibrous histiocytoma, fibrosarcoma and Kaposi's sarcoma.

[[119]] 133. (currently amended) Use according to claim [[111 or 112]] 125 or 126, wherein said cancer is a glioma.

[[120]] 134. (currently amended) A method for treating cancer, said method comprising administering a compound as defined in ~~any of claims 1-105~~ claim 1, a conjugate as defined in claim [[106]] 120 or a pharmaceutical composition as defined in any of claims [[107-109]] 121-123 to a patient in need thereof.

[[121]] 135. (currently amended) The method according to claim [[120]] 134, wherein said cancer is in the form of a solid tumor.

[[122]] 136. (currently amended) The method according to claim [[120]] 134, wherein said cancer is a carcinoma.

[[123]] 137. (currently amended l) The method according to claim [[122]] 136, wherein said carcinoma is selected from the group consisting of malignant melanoma, basal cell carcinoma, ovarian carcinoma, breast carcinoma, non-small cell lung cancer, renal cell carcinoma, bladder carcinoma, recurrent superficial bladder cancer, stomach carcinoma, prostatic carcinoma, pancreatic carcinoma, lung carcinoma, cervical carcinoma, cervical dysplasia, laryngeal papillomatosis, colon carcinoma, colorectal carcinoma and carcinoid tumors.

[[124]] 138. (currently amended) The method according to claim [[123]] 137, wherein said carcinoma is selected from the group consisting of malignant melanoma, non-small cell lung cancer, breast carcinoma, colon carcinoma and renal cell carcinoma.

[[125]] 139. (currently amended) The method according to claim [[124]] 138, wherein said malignant melanoma is selected from the group consisting of superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral melanoma, amelanotic melanoma and desmoplastic melanoma.

[[126]] 140. (currently amended) The method according to claim [[120]] 134, wherein said cancer is a sarcoma.

[[127]] 141. (currently amended) The method according to claim [[126]] 140, wherein said sarcoma is selected from the group consisting of osteosarcoma, Ewing's sarcoma, chondrosarcoma, malignant fibrous histiocytoma, fibrosarcoma and Kaposi's sarcoma.

[[128]] 142. (currently amended) The method according to claim [[120 or 121]] 134 or 135, wherein said cancer is a glioma.

[[129]] 143. (currently amended) Use of a compound as defined in ~~any of claims 1-105~~ claim 1 or as conjugate as defined in claim [[106]] 120 for the ~~preperation~~ preparation of a medicament for the treatment of arteriosclerosis, psoriasis, diabetic retinopathy, rheumatoid arthritis, asthma, warts and allergic dermatitis.

[[130]] 144. (currently amended) Use of a compound as defined in ~~any of claims 1-105~~ claim 1 or as conjugate as defined in claim [[106]] 120 for the manufacture of a medicament for the treatment of cancer, wherein said medicament further comprises a chemotherapeutic agent selected from the group consisting of adrenocorticosteroids, such as prednisone, dexamethasone or decadron; altretamine (hexalen, hexamethylmelamine (HMM)); amifostine (ethyol); aminoglutethimide (cytadren); amsacrine (M-AMSA); anastrozole (arimidex); androgens, such as testosterone; asparaginase (elspar); bacillus calmette-gurin; bicalutamide (casodex); bleomycin (blenoxane); busulfan (myleran); carboplatin (paraplatin); carmustine (BCNU, BiCNU); chlorambucil (leukeran); chlorodeoxyadenosine (2-CDA, cladribine, leustatin); cisplatin (platinol); cytosine arabinoside (cytarabine); dacarbazine (DTIC); dactinomycin (actinomycin-D, cosmegen); daunorubicin (cerubidine); docetaxel (taxotere); doxorubicin (adriamycin); epirubicin; estramustine (emcyt); estrogens, such as diethylstilbestrol (DES); etoposide (VP-16, VePesid, etopophos); fludarabine (fludara); flutamide (eulexin); 5-FUDR (floxuridine); 5-fluorouracil (5-FU); gemcitabine (gemzar);

goserelin (zodalex); herceptin (trastuzumab); hydroxyurea (hydrea); idarubicin (idarubicin); ifosfamide; IL-2 (proleukin, aldesleukin); interferon alpha (intron A, roferon A); irinotecan (camptosar); leuprolide (lupron); levamisole (ergamisole); lomustine (CCNU); mechlorathamine (mustargen, nitrogen mustard); melphalan (alckeran); mercaptopurine (purinethol, 6-MP); methotrexate (mexate); mitomycin-C (mutamucin); mitoxantrone (novantrone); octreotide (sandostatin); pentostatin (2-deoxycoformycin, nipent); plicamycin (mithramycin, mithracin); prorocarbazine (matulane); streptozocin; tamoxifen (nolvadex); taxol (paclitaxel); teniposide (vumon, VM-26); thiotepa; topotecan (hycamtin); tretinoin (vesanoid, all-trans retinoic acid); vinblastine (valban); vincristine (oncovin) and vinorelbine (navelbine).

[[131]] 145. (currently amended) The use according to claim [[130]] 144, wherein the chemotherapeutic agent is selected from taxanes such as Taxol, Paclitaxel or Docetaxel.

[[132]] 146. (currently amended) Use of a compound as defined in ~~any of claims 1-105~~ claim 1 or as conjugate as defined in claim [[106]] 120 for the manufacture of a medicament for the treatment of cancer, wherein said treatment further comprises the administration of a further chemotherapeutic agent selected from the group consisting of adrenocorticosteroids, such as prednisone, dexamethasone or decadron; altretamine (hexalen, hexamethylmelamine (HMM)); amifostine (ethyol); aminoglutethimide (cytadren); amsacrine (M-AMSA); anastrozole (arimidex); androgens, such as testosterone; asparaginase (elspar); bacillus calmette-gurin; bicalutamide (casodex); bleomycin (blenoxane); busulfan (myleran); carboplatin (paraplatin); carmustine (BCNU, BiCNU); chlorambucil (leukeran); chlorodeoxyadenosine (2-CDA, cladribine, leustatin); cisplatin (platinol); cytosine arabinoside (cytarabine); dacarbazine (DTIC); dactinomycin (actinomycin-D, cosmegen); daunorubicin (cerubidine); docetaxel (taxotere); doxorubicin (adriomycin); epirubicin; estramustine (emcyt); estrogens, such as diethylstilbestrol (DES); etoposide (VP-16, VePesid, etopophos); fludarabine (fludara); flutamide (eulexin); 5-FUDR (floxuridine); 5-fluorouracil (5-FU); gemcitabine (gemzar); goserelin (zodalex); herceptin (trastuzumab); hydroxyurea

(hydrea); idarubicin (idamycin); ifosfamide; IL-2 (proleukin, aldesleukin); interferon alpha (intron A, roferon A); irinotecan (camptosar); leuprolide (lupron); levamisole (ergamisole); lomustine (CCNU); mechlorathamine (mustargen, nitrogen mustard); melphalan (alkeran); mercaptopurine (purinethol, 6-MP); methotrexate (mexate); mitomycin-C (mutamucin); mitoxantrone (novantrone); octreotide (sandostatin); pentostatin (2-deoxycoformycin, nipent); plicamycin (mithramycin, mithracin); prorocarbazine (matulane); streptozocin; tamoxifen (nolvadex); taxol (paclitaxel); teniposide (vumon, VM-26); thiotepa; topotecan (hycamtin); tretinoin (vesanoid, all-trans retinoic acid); vinblastine (valban); vincristine (oncovin) and vinorelbine (navelbine).

[[133]] 147. (currently amended) The use according to claim [[132]] 146, wherein said treatment further comprises the administration of a further chemotherapeutic agent selected from taxanes, such as Taxol, Paclitaxel or Docetaxel.

[[134]] 148. (currently amended) A method for treating cancer, said method comprising administering a compound as defined in ~~any of claims 1-105~~ claim 1, a conjugate as defined in claim [[106]] 120 or a pharmaceutical composition as defined in any of claims [[107-109]] 121-123 to a patient in need thereof and further comprising the administration of a [[a]] further chemotherapeutic agent selected from the group consisting of adrenocorticosteroids, such as prednisone, dexamethasone or decadron; altretamine (hexalen, hexamethylmelamine (HMM)); amifostine (ethyol); aminoglutethimide (cytadren); amsacrine (M-AMSA); anastrozole (arimidex); androgens, such as testosterone; asparaginase (elspar); bacillus calmette-gurin; bicalutamide (casodex); bleomycin (blenoxane); busulfan (myleran); carboplatin (paraplatin); carmustine (BCNU, BiCNU); chlorambucil (leukeran); chlorodeoxyadenosine (2-CDA, cladribine, leustatin); cisplatin (platinol); cytosine arabinoside (cytarabine); dacarbazine (DTIC); dactinomycin (actinomycin-D, cosmegen); daunorubicin (cerubidine); docetaxel (taxotere); doxorubicin (adriomycin); epirubicin; estramustine (emcyt); estrogens, such as diethylstilbestrol (DES); etoposide (VP-16, VePesid, etopophos); fludarabine (fludara); flutamide (eulexin); 5-FUDR (floxuridine); 5-fluorouracil

(5-FU); gemcitabine (gemzar); goserelin (zodalex); herceptin (trastuzumab); hydroxyurea (hydrea); idarubicin (idamycin); ifosfamide; IL-2 (proleukin, aldesleukin); interferon alpha (intron A, roferon A); irinotecan (camptosar); leuprolide (lupron); levamisole (ergamisole); lomustine (CCNU); mechlorathamine (mustargen, nitrogen mustard); melphalan (alkeran); mercaptopurine (purinethol, 6-MP); methotrexate (mexate); mitomycin-C (mutamucin); mitoxantrone (novantrone); octreotide (sandostatin); pentostatin (2-deoxycoformycin, nipent); plicamycin (mithramycin, mithracin); prorocarbazine (matulane); streptozocin; tamoxifen (nolvadex); taxol (paclitaxel); teniposide (vumon, VM-26); thiotepa; topotecan (hycamtin); tretinoin (vesanoid, all-trans retinoic acid); vinblastine (valban); vincristine (oncovin) and vinorelbine (navelbine).

[[135]] 149. (currently amended) A method for treating cancer, said method comprising administering a compound as defined in ~~any of claims 1-105~~ claim 1, a conjugate as defined in claim [[106]] 120 or a pharmaceutical composition as defined in any of claims [[107-109]] 121-123 to a patient in need thereof and further comprising the administration of a [[a]] further chemotherapeutic agent selected from the group consisting of taxanes, in particular Taxol, Paclitaxel or Docetaxel.

[[136]] 150. (currently amended) A method of treating a mammal suffering from or susceptible from a disease caused by abnormal angiogenesis, comprising: administering to the mammal an therapeutically effective amount of an oligonucleotide targeted to survivin that comprises one or more LNA units.

[[137]] 151. (currently amended) A method of preventing or limiting apoptosis claims comprising the ~~administration~~ administration of a compound as defined in ~~any of claims 1-105~~ claim 1, a conjugate as defined in claim [[106]] 120 or a pharmaceutical composition as defined in any of claims [[107-109]] 121-123.

[[138]] 152. (currently amended) A method of preventing cellular proliferation comprising the administration of a compound as defined in ~~any of claims 1-105~~ claim 1, a conjugate as defined in claim [[106]] 120 or a pharmaceutical composition as defined in any of claims [[107-109]] 121-123.